The dawn of the liquid biopsy in the fight against cancer Journal Article
| Authors: | Domínguez-Vigil, I. G.; Moreno-Martínez, A. K.; Wang, J. Y.; Roehrl, M. H. A.; Barrera-Saldaña, H. A. |
| Article Title: | The dawn of the liquid biopsy in the fight against cancer |
| Abstract: | Cancer is a molecular disease associated with alterations in the genome, which, thanks to the highly improved sensitivity of mutation detection techniques, can be identified in cell-free DNA (cfDNA) circulating in blood, a method also called liquid biopsy. This is a non-invasive alternative to surgical biopsy and has the potential of revealing the molecular signature of tumors to aid in the individualization of treatments. In this review, we focus on cfDNA analysis, its advantages, and clinical applications employing genomic tools (NGS and dPCR) particularly in the field of oncology, and highlight its valuable contributions to early detection, prognosis, and prediction of treatment response. © Domínguez-Vigil et al. |
| Keywords: | treatment response; unclassified drug; single nucleotide polymorphism; review; nonhuman; polymerase chain reaction; biological marker; microrna; gene expression; tumor biopsy; cancer genetics; dna; molecular evolution; diagnostic value; biopsy technique; dna mutational analysis; dna determination; early detection; genetic heterogeneity; circulating tumor cell; rna analysis; diagnostics; next generation sequencing; cancer prognosis; human; circulating tumor dna; liquid biopsy; early cancer diagnosis; cell free dna; cfdna; malignant neoplasm; ctdna |
| Journal Title: | Oncotarget |
| Volume: | 9 |
| Issue: | 2 |
| ISSN: | 1949-2553 |
| Publisher: | Impact Journals |
| Date Published: | 2018-01-05 |
| Start Page: | 2912 |
| End Page: | 2922 |
| Language: | English |
| DOI: | 10.18632/oncotarget.23131 |
| PROVIDER: | scopus |
| PMCID: | PMC5788692 |
| PUBMED: | 29416824 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 February 2018 -- Source: Scopus |
